Community-acquired methicillin-resistant Staphylococcus aureus, a new player in sports medicine.
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a major pathogen, with distinct clinical characteristics and target populations. It has a striking ability to infect the young and the healthy. Persons in crowded conditions are at risk, including athletes, military personnel, jail inmates, and children in daycare. Most CA-MRSA infections are composed of simple and complicated skin and soft tissue infections; invasive disease occurs in 6% to 10% of cases. CA-MRSA infections can be treated with trimethoprim-sulfamethoxazole, doxycycline, or clindamycin. For severe infections, vancomycin, daptomycin, quinupristin/dalfopristin, or linezolid can be used. Infection control should be an integral part of any CA-MRSA treatment program.
Lu
Doanh
D
Department of Infectious Diseases, Los Angeles County-University of Southern California Medical Center, Los Angeles, CA 90033, USA. doanhlu@gmail.com
Holtom
Paul
P
D017714:Community-Acquired Infections; D006801:Humans; D016106:Methicillin Resistance; D013178:Sports Medicine; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000187:drug effects*